Klacid Hp Special Precautions

Klacid: The physician should not prescribe clarithromycin to pregnant women without carefully weighing the benefits against risk, particularly during the first three months of pregnancy. Long-term use may, as with other antibiotics, result in colonization with increased numbers of non-susceptible bacteria and fungi. If superinfections occur, appropriate therapy should be instituted. Clarithromycin is principally excreted by the liver. Therefore, caution should be exercised in administering the antibiotic to patients with impaired hepatic function. Caution should also be exercised when administering clarithromycin to patients with moderate to severe renal impairment, colchicine, cardiovascular events, Pneumonia, skin and soft tissue infections of mild to moderate severity, HMG-CoA Reductase Inhibitors (statins), oral hypoglycemic agents/insulin, oral anticoagulants and excipients.
In the event of severe acute hypersensitivity reactions, such as anaphylaxis, severe cutaneous adverse reactions (SCAR),(e.g Acute generalized exanthematous pustulosis (AGEP). Stevens-Johnson Syndrome, toxic epidermal necrolysis and DRESS); clarithromyhcin therapy should be discontinued immediately and appropriate treatment should be urgently initiated.
Controloc: Prior to treatment the possibility of malignancy of gastric ulcer or malignant disease of the esophagus should be excluded as the treatment with pantoprazole may alleviate the symptoms of malignant ulcers and can thus delay diagnosis. To date there has been no experience with treatment in children.
Severe Cutaneous Adverse Reactions: Severe cutaneous adverse reactions, including erythema multiforme, Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), drug reaction with eosinophilia and systemic symptoms (DRESS), and acute generalized exanthematous pustulosis (AGEP) have been reported in association with the use of PPIs (see Adverse Reactions). Discontinue pantoprazole at the first signs or symptoms of severe cutaneous adverse reactions or other signs of hypersensitivity and consider further evaluation.
Increased Chromogranin A (CgA) level may interfere with investigations for neuroendocrine tumors. If the patient(s) are due to have a test on CgA level, Controloc treatment should be stopped for at least 5 days before CgA measurements to avoid this interference (see Pharmacology: Pharmacodynamics under Actions). If CgA and gastrin levels have not returned to reference range after initial measurement, measurements should be repeated 14 days after cessation of proton pump inhibitor treatment.
Ospamox: Patients should be told about the potential occurrence of allergic reactions and instructed to report them. If allergic reactions occur, the drug should be discontinued and the usual treatment with epinephrine, antihistamines and corticosteroids should be instituted. If maculopapular amoxycillin rashes develop, treatment should be confined to life-threatening conditions and patients should be carefully monitored. Adequate fluid intake and urine output are essential during treatment. Severe and persistent diarrhea should prompt suspicion of antibiotic-induced pseudomembranous colitis (blood-streaked, mucoid, watery diarrhea; dull diffuse or colicky abdominal pain; fever and occasional tenesms), which may be life-threatening. In pertinent cases Ospamox should immediately be withdrawn and treatment specific for the offending organism (e.g. oral Vancomycin) should be instituted. Antiperistaltic drugs are contra-indicated.